

ASX Announcement

Monash IVF Group Limited (ASX: MVF)

14 January 2022

Temporary suspension of certain IVF procedures in Victoria

Monash IVF Group Limited (ASX: MVF, the “Company” or “Monash IVF”) today provides an update on IVF procedures in Victoria following changes to non-urgent surgery settings to assist Victorian hospitals respond to Omicron.


On 12 January 2022, the Victorian Minister of Health made the Pandemic (Additional Industry Obligations) Order 2022 (No.3) (“Order”) under the Public Health and Wellbeing Act 2008 in the belief that the Order is reasonably necessary to protect public health throughout Victoria from the serious risk arising from the COVID-19 pandemic disease. The Order has the following impact on IVF and is limited to metropolitan Melbourne and major regional cities across Victoria:

- Stimulated Cycles whereby patients have commenced their drug regime prior to 6 January 2022 will continue to complete their stimulated cycle treatment in line with COVID-19 safety protocols;
- For all patients who plan to commence a Stimulated Cycle after 6 January 2022, they will need to undertake a clinical assessment to determine the urgency and whether they can commence treatment based on clause 16(7)(a)(ii) of the Order;
- Frozen Embryo Transfer (FET), Intrauterine Insemination (IUI) and medical fertility preservation procedures are continuing at this time;
- The Order commences from 12 January 2022 and ends at 11:59pm on 12 April 2022. It is yet to be determined if this Order will impact IVF services for the full three-month period.

Monash IVF’s primary objective remains supporting and keeping patients informed and updated on their treatment options during this uncertain time. The Company remains focussed on maintaining appropriate measures and protocols in-place to protect the health and safety of the Company’s patients, employees and specialists. Whilst this is the Company’s primary objective, the Company will continue to seek clarity from the Department of Health on the application of the Order and will continue to work with the Department of Health on a swift recommencement of all IVF services in Victoria.

Similar to the temporary suspension of IVF procedures in March and April 2020, it is the Company’s view that the Order will create pent-up treatment demand which will be services within three to four months following resumption of services.

The Company’s IVF Services in all other Australian States (outside of Victoria) and other relevant countries are not currently impacted by elective surgery restrictions and are continuing. The short-term financial impact of the Order on the FY2022 Financial Result is yet to be determined but is not expected to have a material effect on the FY2022 Financial Result unless the Order restricts IVF services for a period greater than eight weeks from the commencement of the Order.



The Company will provide a further update in due course and/or at the Company's half-year results announcement.

Approved by the Chairman and Managing Director.

Michael Knaap

Chief Executive Officer and Managing
Director, Monash IVF Group
+61 3 9452 8132

Malik Jainudeen

Chief Financial Officer and Company
Secretary, Monash IVF Group
+61 3 9452 8132